+9.85% close: SKIN.SW Cassiopea S.p.A. (SIX) market closed, next steps
SKIN.SW stock led today’s high-volume movers on the SIX, closing at CHF35.70, up 9.85% on volume of 2,756 shares as the market closed on 24 Feb 2026. The move pushed price above the 50-day average CHF34.37 and below the 200-day average CHF37.22, highlighting short-term buying interest. Traders noted a day range of CHF32.00–CHF36.00, lifting volatility after several quiet sessions. This article breaks down the trading drivers, financials, technicals, risks and a model-based forecast to help frame near-term scenarios for SKIN.SW stock.
SKIN.SW stock: Intraday price action and volume drivers
Cassiopea S.p.A. (SKIN.SW) on SIX closed at CHF35.70, a CHF3.20 gain from the previous close CHF32.50. Volume finished at 2,756, which is 1.52x the average volume 1,818, marking a genuine high-volume mover. One clear driver is renewed investor interest in Cassiopea’s dermatology pipeline and recent news flow on clinical programmes. The day’s high CHF36.00 and low CHF32.00 show intraday buying pressure concentrated near the open. The stock’s year range remains CHF25.70–CHF53.00, keeping upside optionality visible to momentum traders.
SKIN.SW stock: Fundamentals and financial snapshot
Cassiopea is a clinical-stage biotech focused on medical dermatology. Trailing metrics show EPS -1.27 and PE -28.13, reflecting negative earnings typical for development-stage firms. Key balance metrics include book value per share CHF1.50, cash per share CHF0.25, and a current ratio 1.98, indicating near-term liquidity cover. Enterprise value metrics are distorted (enterprise value shown negative in the feed), so investors should prioritise cash runway and R&D milestones over standard valuation multiples when assessing SKIN.SW stock.
Meyka AI grade and technical read for SKIN.SW stock
Meyka AI rates SKIN.SW with a score out of 100: 62.51 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technically, the stock trading above the 50-day average CHF34.37 but below the 200-day average CHF37.22 suggests short-term strength inside a longer-term neutral band. Watch the 50–200 day cross and volume spikes for confirmation of trend continuation or failure.
SKIN.SW stock: Catalysts, sector context and risks
Near-term catalysts include clinical updates on Breezula and CB-06-01 and commercial progress for Winlevi. Healthcare sector trends show modest YTD performance versus broader markets, with top peers maintaining stronger profit margins. Key risks: binary clinical outcomes, negative earnings (EPS -1.27) and limited liquidity compared to larger healthcare names. For traders, the high days of inventory 454.61 and extended payables indicate operational quirks; for investors, clinical readouts will likely remain the primary price catalysts for SKIN.SW stock.
SKIN.SW stock: Technical levels and short-term trading strategy
Immediate support sits near CHF32.00 (today’s low) and CHF34.37 (50-day average). Resistance is at CHF36.00 (today’s high) and the 200-day average CHF37.22. Momentum traders may use tight stops under CHF32.00 with target bands toward CHF42.50 if volume sustains. Longer-term investors should tie buys to clinical progress or improved cash flow. Given the high-volume move, intraday traders should manage position size due to thin average liquidity (avg vol 1,818).
SKIN.SW stock forecast and price target
Meyka AI’s forecast model projects a near-term consensus target of CHF42.50, which implies an upside of 19.05% versus the current CHF35.70. That projection factors in historical volatility, sector comparables, and potential positive clinical milestones. Forecasts are model-based projections and not guarantees. Watch for confirmation in upcoming company announcements or regulatory updates before treating the forecast as a trade signal. For more company detail see the official site Cassiopea S.p.A. and the company profile image data FinancialModelingPrep.
Final Thoughts
SKIN.SW stock closed the session at CHF35.70 up 9.85% on 2,756 shares, qualifying it as a clear high-volume mover on SIX on 24 Feb 2026. The swing above the 50-day average CHF34.37 shows renewed interest, but the price is still below the 200-day average CHF37.22, so trend direction is unresolved. Fundamental drivers remain clinical readouts and commercial traction for Winlevi, while liquidity and negative earnings (EPS -1.27) keep risk elevated. Meyka AI’s forecast model projects CHF42.50, implying 19.05% upside from CHF35.70; this is a model projection and not a guarantee. For traders, the intraday structure suggests a momentum trade with tight risk controls. For longer-term investors, wait for clinical or cash runway clarity before adding material exposure. Meyka AI provides this AI-powered market analysis to frame probabilities, but always confirm with primary company disclosures and your own due diligence.
FAQs
What drove the SKIN.SW stock surge today?
High relative volume (2,756 vs avg 1,818) and renewed investor interest in Cassiopea’s dermatology pipeline drove the 9.85% intraday gain. Traders reacted to clinical programme progress and improved intraday technicals that pushed price above the 50-day average.
What is Meyka AI’s grade for SKIN.SW stock?
Meyka AI rates SKIN.SW with a score out of 100: 62.51 | Grade B | Suggestion: HOLD. The grade blends benchmark, sector, growth and key metrics. Grades are informational and not financial advice.
What price target does Meyka AI forecast for SKIN.SW stock?
Meyka AI’s forecast model projects CHF42.50, implying 19.05% upside from the current CHF35.70. Forecasts are model-based projections and not guarantees. Confirm with company updates before trading.
How should traders manage risk on SKIN.SW stock?
Use tight stops near CHF32.00 and size positions for low liquidity. Monitor volume to confirm breakouts above CHF36.00 and watch clinical headlines. Avoid oversized exposure given negative earnings and binary biotech risks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.